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SUPPLEMENTARY NOTES
ABSTRACT
This study has not been fully implemented. Clinical trial regulatory processes have taken more time than anticipated in the Statement of Work. An IND from the FDA to use high-dose vitamin D in the NF1 (neurofibromatosis type 1) population has been obtained, as requested by the University of Utah IRB. There has been one amendment to the original FDA IND approval. The study was approved both by the University of Utah IRB and the DoD USAMRMC ORP HRPO. Ethics board approval from UBC has been approved by HRPO, and U of Cincinnati is under review. The University of Hamburg is working with the European Union Clinical Trials group (EurodratCT) to implement this study, and a document of agreement to perform a joint clinical trial with the University of Utah has been executed. The Clinical Trials office in Hamburg has reviewed the proposal and we have accommodated the custodianship of study drug, cholecalciferol, from the manufacturer in Canada directly to Germany. Reviews from the IRBs and EurodratCT have led to revision of the manual of operations, which is included in this report. We have instituted monthly conference calls, which has enabled us to finalize the manual of ti t Vitamin D therapy appears to have some benefit in treating osteoporosis in the general population, and administration of vitamin D in a dose that maintains the serum 25-hydroxy vitamin D level above 30 ng/mL significantly improves BMD in individuals with NF1. These observations led to the development of a phase II clinical trial to evaluate the effectiveness of vitamin D3 dosing in NF1 patients. This study is designed to assess the efficacy of oral vitamin D3 and calcium therapy to prevent abnormal loss of bone mass in adults with NF1. The clinical trial is a double-blind, dose comparison of efficacy of high-dose versus low-dose vitamin D3 on preservation of bone density as measured by DXA scanning after 2 years of treatment. It compares 2 groups of adults with NF1 between 25 and 40 years of age with insufficient levels of serum 25-hydroxy vitamin D at study entry. Participants are randomized and one group will take 600 IU and the other will take 4,000 IU on a daily basis for 2 years. Participants and investigative teams are blinded to the vitamin D3 dose. The primary outcome measure is bone mineral density at the spine and hip. Secondary patient reported outcome (PRO) measures include a quality of life questionnaire (SF-36), fracture history survey, and activity survey.
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V. Major Goal -Provision of vitamin D3 and calcium supplementation
KEY RESEARCH ACCOMPLISHMENTS -None to report
CONCLUSION:
The implementation of this trial has been delayed for 3 main reasons. The initial assessment by the University of Utah IRB that supplementation of vitamin D required an FDA exemption led to an application that resulted in a denial of exemption, and requirement for an IND for the administration of high-dose (4,000 IU) of cholecalciferol to a selected population of NF1 patients. Approval of an IND through the FDA was obtained in September of 2013. This has been amended in March 2016 to reflect changes in the data collection and safety monitoring. After FDA approval, we could begin the IRB approval process at the University of Utah, which was completed in November of 2013 and reviewed and approved by the DoD HSPO in February of 2014. The next major hurdle has been regulatory compliance with the European Union Clinical Trials organization (EurodratCT) for implementation of a clinical trial through the University of Hamburg. We are working with EurodratCT to finalize our protocol, especially as it relates to the manufacture and transportation of study drug, cholecalciferol. The EurodratCT also required the establishment of a designated legal representative from the sponsoring agency, which was established as the University of Utah. We combined the designated legal representative language with the subcontract, which has been executed. We had anticipated working directly with the University of Hamburg, and the additional regulatory oversight by the EurodratCT was not foreseen in our original application. The administrative costs of this additional regulatory component are provided by the University of Hamburg. Of all 4 sites, HAM is anticipated to have the most adults with NF1 who are insufficient for 25(OH) vitamin D. Without its full participation, it would be nearly impossible to enroll a large enough sample size to achieve statistical significance. We are now poised to complete the ethics review in Germany to begin recruitment in Fall of 2016, and it is anticipated that UBC, CIN, and UTA will be ready to enroll in Fall 2016.
With input from our pediatric clinical trials office (PCTO), we have finalized the manual of operations to reflect the combined needs of all 4 sites and the medical monitoring team. The cost of using the PCTO under new leadership was above what was originally budgeted in the funded proposal, therefore after a teleconference call between the 4 sites we integrated the administrative component of this trial within the Clinical Genetics Research group with Carrie Bailey as the clinical trial manager and the University of Utah Center for Clinical and Translational Sciences.
It is recognized that delays in implementation of the trial will likely lead to cost overrun. Dr. Viskochil has sought no-cost extension approvals to enable funding to the subcontracted sites, and he applied for additional funding from the Childrens Tumor Foundation (CTF) as supplemental funding up to $150,000 as a CTF-sponsored Clinical Trial Award. The full proposal was submitted in Sept 2016 for competitive review.
The electronic database harboring data entry from each of the 4 sites is being developed in REDCAP by Bernie LaSalle in the CCTS (Center for Clinical Translation Sciences).
